Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Nu Holdings Ltd (NU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Nu Holdings Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Nu Holdings Ltd trades at $13.71 (market cap $66.47B). The key difference: Nu Holdings Ltd is the larger of the two by market cap, and Nu Holdings Ltd is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | NU | |
|---|---|---|
Market Cap | $39.89B | $66.47B |
Sector | Health | Financials |
52-Week High | $491.22 | $18.76 |
52-Week Low | $278.09 | $11.60 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
NU Holdings Ltd. (NU) trades at $13.76, up 0.66% on the day, with a bullish technical signal from moving averages and strong fundamental growth. Revenue grew to $10.63B in 2025 with net income of $2.87B, and the company recently secured authorization for its Mexican banking operations, expanding its Latin American footprint. Analyst consensus is a Buy with a $14.98 price target, though recent quarterly EPS results have missed expectations.
The outlook for NU remains positive due to robust revenue growth and expansion potential, but risks include currency headwinds and competitive pressures. The stock's current valuation at a P/E of 21.22 and P/S of 5.67 reflects its growth trajectory, yet investors should monitor execution risks in new markets and credit portfolio performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →
